JW Pharmaceutical announced on June 12 that the indication for its high-dose iron injection 'Perrinject' (active ingredient: ferric carboxymaltose) has been expanded to include patients aged 1 to 13 years.
In this regard, JW Pharmaceutical recently received approval from the Ministry of Food and Drug Safety to add dosage and administration information for pediatric patients aged 1 year and older.
Perrinject is a high-dose iron injection that can replenish up to 1,000 mg of iron in as little as 15 minutes per day. It is used not only for women or patients with chronic bleeding who are at high risk of iron deficiency or iron deficiency anemia, but also for the treatment of iron deficiency anemia caused by various surgeries involving bleeding and chemotherapy-induced iron deficiency anemia.
Iron is an essential mineral that activates various functions in the body, including oxygen transport, enhancement of immune function, cognitive function, fetal development, and energy production. A lack of iron can lead to symptoms such as dizziness, fatigue, shortness of breath, palpitations, and headaches.
With this expanded indication, Perrinject can now be used in patients of all ages except those under 1 year old. Previously, Perrinject was not recommended for pediatric patients under 14 years of age.
According to the revised indication, for children aged 1 to 13 years, the maximum single dose is limited to 15 mL (750 mg of iron) or 0.3 mL per kg of body weight (15 mg of iron), whichever is lower. Administration of 15 mL (750 mg of iron) is allowed up to once per week. If the total required amount of iron exceeds this, additional doses may be administered at intervals of at least 7 days after the initial dose.
Following the inclusion of Perrinject in the national health insurance coverage in May last year, JW Pharmaceutical plans to further improve accessibility and utilization in clinical settings and strengthen its market competitiveness through this expansion of the eligible age group.
A JW Pharmaceutical representative stated, "With this revised approval, Perrinject can now be used in a wider range of age groups, allowing us to provide treatment opportunities to more patients," adding, "We expect this will offer substantial benefits in treating iron deficiency in pediatric patients."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
